Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

63
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
63
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

76
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
76
Positron Emission Tomography01:29

Positron Emission Tomography

3.9K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of Capillary Permeability Using Radiolabeled Albumin and 3D CZT-ring Gamma Camera.

Clinical nuclear medicine·2026
Same author

Balancing innovation and accessibility in infection imaging: lessons from the [<sup>99m</sup>Tc]Tc-besilesomab paradox.

EJNMMI radiopharmacy and chemistry·2026
Same author

Evaluation of precalculated attenuation correction map for preclinical cardiac PET/MR using a <sup>1</sup>H/<sup>23</sup>Na surface coil.

EJNMMI physics·2026
Same author

Renal dynamic scintigraphy using 3D-ring CZT cameras: comparison with NaI(Tl).

EJNMMI research·2025
Same author

Microvascular Dysfunction Assessed by 82 Rb PET/CT as a Diagnostic Tool of Chronic Active Myocarditis.

Clinical nuclear medicine·2025
Same author

Calcium scoring during 18F-FDG PET/CT in cancer indications: Improving cardiovascular risk stratification and prevention.

PloS one·2025

Related Experiment Video

Updated: May 20, 2025

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.4K

Gallium-Labeled PET Radiopharmaceuticals in Cardiovascular Disease.

Matthieu Bailly1,2, Anne Claire Dupont3, Guillaume Domain4

  • 1Nuclear Medicine Department, CHU Orleans, 45100 Orléans, France.

Pharmaceuticals (Basel, Switzerland)
|March 27, 2025
PubMed
Summary

Gallium-68 (⁶⁸Ga) tracers are revolutionizing cardiovascular disease imaging by visualizing inflammation and fibrosis. These positron emission tomography (PET) probes offer precise diagnostics and personalized treatment strategies.

Keywords:
CXCR4DOTAFAPIcardiovasculargallium-labeled radiopharmaceuticalsmyocardial infarctionmyocarditissarcoidosis

More Related Videos

Investigations on the GaIII Complex of EOB-DTPA and Its 68Ga Radiolabeled Analogue
11:22

Investigations on the GaIII Complex of EOB-DTPA and Its 68Ga Radiolabeled Analogue

Published on: August 17, 2016

9.9K
High-Resolution Cardiac Positron Emission Tomography/Computed Tomography for Small Animals
11:09

High-Resolution Cardiac Positron Emission Tomography/Computed Tomography for Small Animals

Published on: December 16, 2022

2.8K

Related Experiment Videos

Last Updated: May 20, 2025

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.4K
Investigations on the GaIII Complex of EOB-DTPA and Its 68Ga Radiolabeled Analogue
11:22

Investigations on the GaIII Complex of EOB-DTPA and Its 68Ga Radiolabeled Analogue

Published on: August 17, 2016

9.9K
High-Resolution Cardiac Positron Emission Tomography/Computed Tomography for Small Animals
11:09

High-Resolution Cardiac Positron Emission Tomography/Computed Tomography for Small Animals

Published on: December 16, 2022

2.8K

Area of Science:

  • Nuclear Medicine
  • Molecular Imaging
  • Cardiology

Background:

  • Gallium-labeled positron emission tomography (PET) probes targeting activated fibroblasts or somatostatin receptors are vital in oncology.
  • ⁶⁸Ga tracers, enabled by ⁶⁸Ge/⁶⁸Ga generators, are now central to molecular imaging.
  • Tracers like [⁶⁸Ga]Ga-DOTA-TATE, [⁶⁸Ga]Ga-FAPI, and [⁶⁸Ga]Ga-pentixafor visualize key pathological processes.

Purpose of the Study:

  • To review the potential of ⁶⁸Ga-based PET tracers in cardiovascular diseases.
  • To highlight their utility in diagnosing and managing conditions such as myocardial infarction, cardiac sarcoidosis, myocarditis, and cardiomyopathies.
  • To discuss the role of these tracers in predicting outcomes and guiding therapy.

Main Methods:

  • Review of clinical and preclinical studies utilizing ⁶⁸Ga-based PET tracers.
  • Analysis of tracer applications in visualizing inflammation, fibrosis, and necrosis in cardiovascular conditions.
  • Evaluation of diagnostic and prognostic value in various cardiomyopathies.

Main Results:

  • ⁶⁸Ga tracers effectively visualize active disease processes in cardiovascular conditions.
  • Studies demonstrate their utility in predicting patient outcomes.
  • These tracers aid in guiding therapeutic strategies for cardiovascular diseases.

Conclusions:

  • ⁶⁸Ga-based PET is a promising modality for cardiovascular disease diagnosis.
  • It enhances diagnostic precision and enables personalized treatment approaches.
  • Further standardization and larger clinical trials are needed for routine integration.